Results 11 to 20 of about 13,250 (289)

A Retrospective Study of Lung Transplantation in Patients With Lymphangioleiomyomatosis: Challenges and Outcomes

Frontiers in Medicine, 2021
Background: Lymphangioleiomyomatosis (LAM) is a rare systemic disease that generally leads to a progressive decline in pulmonary function. Experience, especially from the Asian population, including combined drug therapy before and after lung ...
Ji Zhang, Dong Liu, Bingqing Yue, Le Ban, Min Zhou, Hongmei Wang, Jian Lv, Bo Wu, Zhenguo Zhai, Zhenguo Zhai, Kai-Feng Xu, Wenhui Chen, Jingyu Chen, Jingyu Chen   +13 more
doaj   +2 more sources

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis

EMBO Molecular Medicine, 2021
Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment.
Carmen Herranz, Francesca Mateo, Alexandra Baiges, Gorka Ruiz de Garibay, Alexandra Junza, Simon R Johnson, Suzanne Miller, Nadia García, Jordi Capellades, Antonio Gómez, August Vidal, Luis Palomero, Roderic Espín, Ana I Extremera, Eline Blommaert, Eva Revilla‐López, Berta Saez, Susana Gómez‐Ollés, Julio Ancochea, Claudia Valenzuela, Tamara Alonso, Piedad Ussetti, Rosalía Laporta, Antoni Xaubet, José A Rodríguez‐Portal, Ana Montes‐Worboys, Carlos Machahua, Jaume Bordas, Javier A Menendez, Josep M Cruzado, Roser Guiteras, Christophe Bontoux, Concettina La Motta, Aleix Noguera‐Castells, Mario Mancino, Enrique Lastra, Raúl Rigo‐Bonnin, Jose C Perales, Francesc Viñals, Alvaro Lahiguera, Xiaohu Zhang, Daniel Cuadras, Coline H M van Moorsel, Joanne J van der Vis, Marian J R Quanjel, Harilaos Filippakis, Razq Hakem, Chiara Gorrini, Marc Ferrer, Aslihan Ugun‐Klusek, Ellen Billett, Elżbieta Radzikowska, Álvaro Casanova, María Molina‐Molina, Antonio Roman, Oscar Yanes, Miquel A Pujana   +56 more
doaj   +2 more sources

Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response

The Journal of Pathology: Clinical Research, 2020
Lymphangioleiomyomatosis (LAM) is a rare multisystem disease with a variable clinical course. The lungs are infiltrated by nodules of LAM cells, stromal cells and inflammatory cells, causing lung cysts and respiratory failure. We used immunohistochemical
Suzanne Miller, Iain D Stewart, Debbie Clements, Irshad Soomro, Roya Babaei‐Jadidi, Simon R Johnson   +5 more
doaj   +2 more sources

Real-Time Identification of Lymph Vessels Using Indocyanine Green in a Patient With Chylothorax Associated With Lymphangioleiomyomatosis. [PDF]

Asian J Endosc Surg
ABSTRACT Introduction Lymphangioleiomyomatosis (LAM) is often complicated by chylothorax and may require surgical intervention; however, the treatment is complicated because of difficulties in identifying the location of the fistula intraoperatively.
Sakamoto S, Toba H, Baba A, Takehara E, Fujimoto K, Takeuchi T, Sumitomo H, Miyamoto N, Morishita A, Kawakita N, Takizawa H.   +10 more
europepmc   +2 more sources

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis

Proceedings of the National Academy of Sciences of the United States of America, 2022
Significance The current application of messenger RNA (mRNA)-based technology has largely been confined to liver diseases because of the lack of a specific and efficient extrahepatic in vivo systemic mRNA delivery system.
Min Qiu, Yan Tang, Jinjin Chen, Rachel E Muriph, Zhongfeng Ye, Changfeng Huang, Jason J Evans, E. Henske, Qiaobing Xu   +8 more
semanticscholar   +1 more source

Lymphangioleiomyomatosis: Searching for potential biomarkers

Frontiers in Medicine, 2023
Background Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of
Eva Revilla-López, V. Ruiz de Miguel, M. López-Meseguer, C. Berastegui, Meritxell Boada-Pérez, A. Mendoza-Valderrey, Marta Arjona-Peris, Marta Zapata-Ortega, V. Monforte, C. Bravo, A. Roman, S. Gómez-Ollés, B. Sáez-Giménez   +12 more
semanticscholar   +1 more source

Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells

Science Advances, 2023
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry TSC1/TSC2 mutations, causing mTORC1 hyperactivation and uncontrolled cell growth.
Tasnim Olatoke, A. Wagner, A. Astrinidis, E. Zhang, M. Guo, Alan G. Zhang, Ushodaya Mattam, E. Kopras, N. Gupta, Eric P. Smith, M. Karbowniczek, M. Markiewski, K. Wikenheiser-Brokamp, J. Whitsett, F. McCormack, Yan Xu, Jane J. Yu   +16 more
semanticscholar   +1 more source

The Epidemiology and Clinical Features of Lymphangioleiomyomatosis (LAM): A Descriptive Study of 33 Case Reports

Cureus, 2023
Lymphangioleiomyomatosis (LAM) is a rare, slow-growing metastasizing neoplasm in which smooth muscle-like cells infiltrate the lung parenchyma and cause cystic lung damage.
Jaini Shah, Jaimin T Patel, Hriday M. Shah, Harika Dadigiri, Arya Alla, P. Cheriyath   +5 more
semanticscholar   +1 more source

A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) [PDF]

, 2014
Lymphangioleiomyomatosis (LAM) is a rare and progressive cystic lung condition affecting approximately 3.4-7.5/million women, with an average lag time between symptom onset and diagnosis of upwards of 4 years. The aim of this work was to identify altered
Banville, N, Black, JL, Burgess, JK, Cerri, S, Jaffar, J, Oliver, BG, Persiani, E, Richeldi, L, Tjin, G   +8 more
core   +9 more sources

Sporadic Lymphangioleiomyomatosis Disease: A Case Report [PDF]

Iranian Journal of Medical Sciences, 2023
Pulmonary Lymphangioleiomyomatosis (LAM) is a rare disease of the lung and lymphatic system that primarily affects women of childbearing age. LAM is a progressive disease with a terrible prognosis, which worsens over time and is extremely difficult to ...
Yousef Nikmanesh, Mansoureh Shokripour, Maral Mokhtari, Mahdi Khazayi, Ahmad Monabati, Ramin Rezayi, Mehrzad Bahtouee   +6 more
doaj   +1 more source